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Abstract
Background
Tenofovir (TDF) can cause kidney injury through tubular dysfunction, with or without drop of
estimated glomerular filtration rate (eGFR).Whethermild eGFR reductions during treatment
should be considered a reason for prompt TDF discontinuation, however, remains unclear.
Methods
Patients with normal pre-TDF eGFR levels, who had developed mild renal impairment (i.e.,
two consecutive eGFR results between 89–60ml/min) on TDF, were observed until onset
of chronic kidney disease (CKD), defined as two eGFR<60ml/min 3 to 6 months apart.Mul-
tivariable Poisson regression analysis was used to investigate whether outcomewas asso-
ciated with current and cumulative use of TDF (modeled as time-varying covariates).
Results
2023 (29%) out of 6984 patients developed mild renal impairmenton TDF. Among them,
191 progressed to CKD. The incidence of CKD did not significantly differ during TDF treat-
ment (2.6 per 100 PYFU; 95%CI 2.2–3.2) or after its discontinuation (2.2 per 100 PYFU;
95%CI 1.8–2.6). However, the rate of CKD was significantly higher among patients continu-
ing with TDF treatment compared to those who had discontinued it within 6 months of occur-
rence of mild renal impairment (aIRR 4, 95%CI 2.4–6.8). In contrast, among patients who
had maintained TDF >6 months despite mild renal impairment, current TDF use was not
associated with a significantly higher rate of CKD. Other significant predictors of CKD were
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Conclusions
Prompt discontinuation of TDF among patients developing mild renal impairmentmay pre-
vent furtherprogression of renal damage.
Background
Tenofovir disoproxil fumarate (TDF) is widely used as a component of combination antiretro-
viral treatment (cART). The main adverse event associated with the use of TDF is nephrotoxi-
city with tubular dysfunction, with or without the reduction of glomerular filtration rate
(GFR). Because TDF is excreted mainly in unchanged form by the kidneys, its clearance is sig-
nificantly reduced in patients with moderate or severe renal impairment. In such patients, TDF
use is preferentially avoided.[1] However, few studies have explored the safety of TDF in
patients experiencingmild GFR reduction (i.e., between 89 and 60 ml/min).Whether, under
these circumstances, TDF should be discontinued, remains a topic of debate. Previous observa-
tional studies have yielded conflicting results about the risk of progressive renal damage owing
to prolonged exposure to TDF. Some studies have demonstrated an association between cumu-
lative exposure to TDF and risk of chronic kidney disease (CKD), even among patients with
normal renal function before TDF introduction.[2–4],Other studies, however, have suggested
that loss in kidney function occursmostly during the first year of TDF exposure and that risk
of progression is relatively mild in the long term.[5,6] Adding to the uncertainty, a reduction in
risk of kidney disease events after TDF discontinuation was found in some studies, but not in
others. [3,4]
Hence, the best course to take in treating patients who develop mild renal impairment
whilse on TDF has yet to be determined.As a consequence, the decision of whether to replace
or suspend TDF often is up to the personal judgment of the physician.
Aims of our study were to evaluate the incidence of chronic kidney disease among patients
who developedmild renal impairment during TDF treatment, to assess the risk of evolution to
CKDwhile continuing TDF treatment compared versus discontinuing it and, lastly, to identify
factors associated with the evolution to CKD.
Methods
Patients were recruited from the observational Italian MASTER database cohort.
The MASTER cohort study was approved by the Ethics Committee of each participating
center (Comitato Etico Provinciale della Provincia di Brescia, Comitato Etico della Provincia di
Bergamo, Comitato Etico dell'AziendaOspedaliera Policlinico Consorziale di Bari, Comitato
Etico per la sperimentazione clinica dei medicinali dell'azienda sanitaria di Firenze, Comitato
Etico della Provincia di Ferrara, Comitato Etico della Provincia Monza Brianza, Comitato
Etico dell'AziendaOspedaliera Istituti Ospitalieri di Cremona, Comitato Etico dell'Università
del Sacro Cuore—Policlinico Universitario Agostino Gemelli di Roma).Written informed con-
sent is obtained from the participants to the cohort upon enrollment. No specific consent was
obtained for the present analysis.
Detailed description of the MASTER cohort is contained elsewhere.[7] Briefly, it is an ongo-
ing prospectivemulticentre cohort which includes all patients in care for HIV infection in
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selected Italian clinical centers who have provided written informed consent to include their
clinical and biological data in the MASTER database for scientific purposes. Patients are rou-
tinely seen every 3–4 months, and demographic, laboratory, clinical and treatment information
are collected during each visit. Data are collected using a common electronic database, utilized
by each participating centre for clinical purposes, and data is centralized,merged and checked
for consistency on a 6-month basis. The database used for the present analysis was frozen in
November 2014 and includes data from 8 clinical centers: Bari, Brescia, Bergamo, Cremona,
Ferrara, Florence, Monza and Rome.HIV-1 infected patients who, between 2002 and 2013 had
begun TDF treatment for the first time as part of an antiretroviral regimen were selected from
the cohort if:
• estimated GFR (eGFR) before TDF introduction was>90 ml/min and
• they had developedmild renal impairment, defined as two consecutive eGFR between 89 and
60 ml/min, during TDF.
Estimated GFR was calculated using the Chronic Kidney Disease Epidemiology Collabora-
tion (CKD-EPI) formula.[8]
Incidence rates of CKD, defined as two eGFR<60 ml/minmeasured 3 to 6 months apart,
was calculated as events per 100 patient-years of follow-up (PYFU), together with relative 95%
confidence intervals, based on an exact Poisson distribution. A Poisson regression model was
fitted to estimate the association between current TDF use and incidence of CKD. Follow-up
accrued from the second of the two consecutive eGFR definingmild renal impairment (study
baseline) up to the development of CKD, or to the last available eGFRmeasurement. A multi-
variable analysis was carried out adjusting for several time-fixed factors: age, gender, country
of birth, risk factor for HIV transmission, hepatitis C virus (HCV) co-infection (defined as
serum reactivity for HCV-RNA or HCV-antibody positivity with unknownHCV-RNA), hepa-
titis B virus (HBV) surface antigen positivity, diagnosis of diabetes or hypertension, history of
exposure to antiretroviral drugs prior to TDF introduction, use of boosted protease inhibitors,
CD4+ T-cell count and eGFR preceding TDF introduction, eGFR drop betweenTDF introduc-
tion and occurrence of mild renal impairment, and cumulative exposure to TDF at the time of
occurrence of mild renal impairment. Additionally, in order to investigate whether the effects
of TDF current use might vary in relation to cumulative exposure to TDF since onset of mild
renal impairment, we included an interaction term between these two time-dependent vari-
ables. The latter of these two variables was divided into four categories (<6 months, 6–12
months, 1–2 years,>2 years)
An additional analysis was carried out, in order to assess the impact of TDF discontinuation
on yearly decline of eGFR.A multivariate linear model was fitted, using GeneralizedEstimating
Equations method, to account for the clustered structure of data, i.e. time-dependent eGFR
measurement within patients. This model was adjusted for the same time-fixed covariates listed
above.
All statistical analyses were performed using R software version 3.2.2.
Results
A total of 8,862 patients enrolled in the MASTER cohort initiated TDF for the first time,
between January 1st 2002 and December 31st 2013. We excluded 1,575 patients whose eGFR
before TDF was<90 ml/min, 229 who lacked eGFR determinations prior to TDF, and an addi-
tional 74 who lacked creatinine follow-up after TDF initiation. Among the 6,984 patients who
had initiated cART regimens which included TDF when their eGFR was>90 ml/min, 2,023
(29%) developedmild renal impairment (i.e., two consecutive eGFR between 89 and 60 ml/
Chronic Kidney Disease during Tenofovir
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min). These patients were therefore selected for all subsequent analyses. Most patients were
male and Caucasians, with a mean age of 44 years (range 18–75). Their mean eGFR had
dropped, after TDF introduction, from 104 to 80 ml/min. In about a quarter of the cases (494/
2,023 = 24.4%), mild renal impairment was diagnosedwithin 6 months of TDF treatment.
Table 1 illustrates, in detail, these occurences, as well as other characteristics at the time of the
diagnosis of mild renal impairment. Subsequent to study inclusion, the median number of
eGFRmeasurements per patient was 15 [inter-quartile range (IQR) 7–25], with a median gap
of 3 months (IQR 2–4) betweenmeasurements. The median time between consecutive eGFR
measurements did not differ significantly during TDF treatment and after its discontinuation
Table 1. Characteristics of patientsdevelopingmild renal impairment under TDF.
Characteristic
Gender,male—N (%) 1396 (69.0)
Age, years—mean (sd) 44.1 (8.4)
Place of birth, N (%)
Europe/NorthAmerica 1930 (95.4)
Africa 50 (2.5)
Other 43 (2.1)
HIV transmission route, N (%)
Heterosexual intercourse 781 (44.0)
Homosexual intercourse 186 (10.5)
Intravenous Drug use 618 (34.8)
Other/unreported 192 (10.8)
Historyof AIDS defining events, N (%) 522 (25.8%)
Time since inclusion in the cohort, years–mean (sd) 8.9 (7.2)
HBsAg positivity, N (%) 243 (12.0)
HCVAb/HCV-RNA positivity, N (%) 559 (27.6)
Diabetes, N (%) 194 (9.6)
Hypertension, N (%) 527 (26.1)
Previously naïve to antiretroviral treatment, N (%) 656 (32.4)
Boosted-PI co-administration, N (%) 1529 (75.6)
CD4+ T-cell count, cells/μl–mean (sd) 341 (239)
Nadir CD4+ T-cell count, cells/μl–mean (sd) 180 (136)
HIV-RNA at TDF introduction, N (%
<50 copies/ml 686 (33.9)
51–1,000 copies/ml 196 (9.7)
1,001–10,000 copies/ml 206 (10.2)
10,001–100,000 copies/ml 474 (23.4)
>100,000 copies/ml 400 (19.8)
Weight, kg–mean (sd) 68.7 (13.6)
eGFR before TDF introduction, ml/min–mean (sd) 104.2 (9.2)
eGFR drop since TDF introduction,ml/min–mean (sd) 24 (13.7)
Time on TDF, years 3.6 (2.5)
eGFRwas calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.[8]Mild
renal impairmentwas defined as two consecutive eGFR between 89 and 60 ml/min during TDF treatment.
Abbreviations: eGFR, estimated glomerular filtration rate; HBsAg, Hepatitis B surface antigen; HCV-Ab,
Hepatitis C virus antibodies; HCV-RNA, Hepatitis C ribonucleic acid; N, number; PI, protease inhibitor, sd,
standard deviation, TDF, tenofovir disoproxil fumarate.
doi:10.1371/journal.pone.0162320.t001
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(3 vs 2.9 months, P>0.05). MInimal correlation between average (within-patients) eGFR values
and the frequency of eGFRmeasurements was observed (spearman rho = 0.24).
One hundred ninety-one out of 8,006 PYFU at risk subsequently developedCKD, account-
ing for an incidence of 2.39 events per 100 PYFU (95%CI 2.07–2.74). Of these, 101 developed
CKD during TDF-containing cART, whilst 90, developedCKD after TDF, had already been
discontinued, accounting for an incidence of 2.63 (95%CI 2.17–3.19) and 2.16 (95%CI 1.76–
2.65) per 100 PYFU, respectively (Fig 1).
Overall, no statistically significant difference was observedwhen comparing the incidence
rate of CKD during TDF with respect to the rate found after its discontinuation (incidence rate
ratio [IRR]: 1.22; 95%CI 0.91–1.61). This result was confirmed using a multivariable analysis
(adjusted IRR [aIRR] 1.12; 95%CI 0.79–1.59), adjusted for age, gender, country of birth, HIV
risk factor, HCV and HBV coinfection, presence of diabetes or hypertension, baseline and pre-
TDF eGFR, CD4+ cell count, previous ARV experience, use of boosted-PI and calendar year.
Nonetheless, current use of TDF was associated with CKD when groups homogeneous for
TDF exposure after onset of mild renal impairment were compared to each other. As shown in
Fig 2, the rate of CKDwas significantly higher among patients on TDF treatment regimens,
compared to those who had discontinued it within 6 months since the diagnosis of mild renal
impairment (aIRR 4.02, 95%CI 2.38–6.78). In contrast, current TDF use was not associated
with a significantly higher risk of CKD among those patients who had stayed on TDF for more
than 6 months after diagnosis of mild renal impairment, (aIRR 0.71 [95%CI 0.19–2.62], 0.51
[95%CI 0.22–1.18] and 0.84 [95%CI 0.5–1.42] among patients who had maintained TDF for
6–12 months, 1–2 years and>2 years after the diagnosis mild renal impairment, respectively).
Using multivariable analysis, the following factors were also significantly and independently
associated with higher rate of CKD: older age (per 1 year increase, aIRR 1.06, 95%CI 1.03–
1.09), intravenous drug use as risk factor for HIV acquisition (versus heterosexual risk factor,
aIRR 2.27, 95%CI 1.38–3.73), diabetes (aIRR 1.58, 95%CI 1.02–2.44), hypertension (aIRR 1.61,
95%CI 1.11–2.31), higher eGFR drop betweenTDF introduction and study baseline (perml/min
Fig 1. Incidence of chronic kidney disease amongpatientswho developedmild renal impairment during
tenofovir-containingantiretroviral treatment.eGFRwas calculated using Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) formula.[8]Mild renal impairment was defined as two consecutive eGFR
between 89 and 60ml/min during TDF treatment.Chronic Kidney Diseasewas defined as two eGFR <60ml/min
measured 3–6months apart.Abbreviations: Pt-yrs, patient-years; TDF, tenofovir disoproxil fumarate.
doi:10.1371/journal.pone.0162320.g001
Chronic Kidney Disease during Tenofovir
PLOSONE | DOI:10.1371/journal.pone.0162320 September 15, 2016 5 / 11
lost, aIRR 1.07, 95%CI 1.06–1.09), and longer TDF exposure prior to onset of mild renal
impairment (per year increase, aIRR 1.19, 95%CI 1.06–1.34). In contrast, higher eGFR before
TDF introductionwas associatedwith a significantly lower incidence of progression to CKD (per
1 ml/min increase, aIRR 0.94, 95%CI 0.92–0.97). No statistically significant effect was exerted by
gender, country of origin, calendar year, hepatitis co-infection, co-administration of boosted-PI,
previous ARV exposure and CD4+ count.
As illustrated in Table 2, the estimated annual rate of eGFR decline after TDF discontinua-
tion was 2.6 (95%CI -0.91 to -4.3) ml/min/year. Patients stayng on TDF experienced an addi-
tional eGFR decline of 2.15 (95%CI -0.98 to -3.42) ml/min/year, corresponding to a mean
eGFR reduction of 4.7 ml/min per year. Progression of renal impairment was seen to be at a
lower rate in older patients with respect to their younger counterparts (eGFR per 1 year older:
+0.15 [95%CI 0.07–0.23] ml/min/year), as well as in those patients who were taking TDF as
part of their first cART, compared to those with previous exposure to antiretrovirals (+2.0
[95%CI 0.33–3.72] ml/min/year).
A multivariable Poisson regression model, aimed at assessing discontinuation rates of TDF,
showed that higher eGFR (per ml/min increase, aIRR 0.99, 95% CI 0.984–0.996) and older age
(per 1 year increase, aIRR 0.99, 95% CI 0.979–0.999) were significantly and independently
associated with a lower risk of TDF discontinuation. No statistically significant association was
found between discontinuation rate of TDF and the other explored covariates, including HIV
risk factor, hepatitis co-infection, diabetes, hypertension and eGFR before TDF initiation (data
not shown).
Among the 101 patients who had developedCKDwhilst on TDF treatment, 62 subsequently
discontinued TDF. After TDF discontinuation, eGFR improved to>60 ml/min in 37 cases,
Fig 2. Association betweencurrent TDF use andCKD, based on cumulative exposure to TDF aftermild
renal impairment occurrence. eGFRwas calculated using Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula.[8]Chronic Kidney Disease was defined as two eGFR <60ml/minmeasured 3–6months apart.
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; TDF, tenofovir disoproxil fumarate.
doi:10.1371/journal.pone.0162320.g002
Chronic Kidney Disease during Tenofovir
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and remained at 30–60 ml/min or<30 ml/min in 20 and 5 cases, respectively. Follow-up after
CKD development was available for only 52/90 patients who had developedCKD after TDF
discontinuation. Among these, the last available eGFR was>60 ml/min, 30–60 ml/min and
<30 ml/min in 19, 28 and 5 cases, respectively.
Discussion
In this observational study of patients with previously normal eGFR, almost one third of the
patients developedmild renal impairment during TDF-containing treatment. Further progres-
sion to CKDwas, however, relatively rare, occurring in<3 cases per 100 patient-years of fol-
low-up, despite the presence of establishedmild renal impairment. Previous randomized
controlled trials of TDF reported very low prevalence of renal toxicity and, although small dif-
ferences in glomerular filtration rate over time were noted, eGFR decline associated with TDF
use was not considered to be clinically relevant.[9–11] Similarly, a systematic review and meta-
analysis suggested that TDF-containing regimens were associated with a significantly greater
loss of eGFR than regimens not containing TDF, although the magnitude of the effect was
modest in clinical terms.[12] Nonetheless, several observational studies have demonstrated an
association betweenTDF use and an increased risk of CKD, even among patients with normal
renal function prior to cART initiation. [2–4,13]Whether initial mild kidney-functiondeterio-
ration during TDF treatment are likely to worsen or stay relatively stable over time is unknown.
Certain studies have suggested that prolonged TDF exposure increases risk of eGFR decline.
[2,4,14] In other studies the loss in eGFR attributable to TDF was observedmainly during the
Table 2. Mean eGFR annual change (ml/min) amongpatientsdevelopingmild renal impairment during treatmentwith tenofovir. Results from the
GEEmultivariate linearmodel.
Adjustedestimate Lower 95%CI Upper 95%CI P
Intercept* -2.6 -4.29 -0.91 0.003
Male gender 0.95 -0.51 2.4 0.202
Age, per year 0.15 0.07 0.23 <0.001
Non-European heritage -0.29 -3.94 3.35 0.874
Risk factor for HIV acquisition
Heterosexual Ref.
Homosexual 0.66 -1.77 3.10 0.593
Intravenous drug abuse 0.75 -1.05 2.55 0.416
Other 0.86 -0.74 2.46 0.292
Current TDF use (versusdiscontinued) -2.16 -3.42 -0.90 <0.001
Pre-TDF eGFR, per mL/min -0.06 -0.17 0.05 0.277
Calendar year at TDF introduction
Before 2005 Ref.
2005–2006 -1.71 -3.18 -0.24 0.022
After 2006 -1.95 -3.62 -0.28 0.022
HBsAg positivity 0.041 -1.84 1.92 0.966
HCVAb/HCV-RNA positivity 0.31 -1.39 2.01 0.72
Diabetes 0.58 -1.28 2.45 0.539
Hypertension 1.00 -0.42 2.43 0.167
Naïve to ARV (vs experienced) 2.02 0.33 3.72 0.019
CD4+ before TDF introduction, per 10 cell/mm3 0.02 -0.003 0.05 0.082
Boosted-PI coadministration -0.05 -1.28 1.19 0.943
*Mean eGFR annual change (ml/min) for the reference patient (with average age, Pre-TDF eGFR and CD4+ before TDF introduction).
doi:10.1371/journal.pone.0162320.t002
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first 6–12 months of exposure, and remained relatively constant afterwards.[5,15] The signifi-
cance of subtle eGFR changes during TDF is, therefore, difficult to interpret in the clinical set-
ting; hence the need to discontinue TDF whenmild eGFR reduction is observed remains
unknown.
In our cohort, switching away from TDF was associated with a lower risk of further progres-
sion of renal damage to CKD, but only if the switch occurredwithin 6 months from onset of
mild renal impairment. In other words, among patients who were kept on TDF for more than
6 months despite the presence of mild renal impairment, a delayed TDF discontinuation did
not apparently affect subsequent eGFR decline. Tenofovir toxicity is principally exerted on the
proximal tubule, where it can accumulate and cause progressive mitochondrial DNA depletion
and oxidative respiratory chain dysfunctions, ultimately leading to degenerative changes and
cell apoptosis.[16,17] Among patients with mild renal impairment, initial modest eGFR reduc-
tions are likely to reflect, at least in part, impairment of active creatinine secretion across the
tubule, rather than a reduction of glomerular filtration.[15] One possible explanation of our
findings is that these tubule alterations are more likely to regress if the insult is withdrawn on a
timely basis. However, if the discontinuation of the drug is delayed, progressive tubule loss and
tissue scarring, and eventual damage to other renal structures (e.g. the glomeruli), can occur,
turning a transient damage into a permanent impairment. Once irreversible damage is estab-
lished, belated treatment switches may fail to significantly reduce the risk of CKD. Consistent
with this hypothesis, previous reports have showed that a significant proportion of patients suf-
fering from acute renal failure associated with TDF fail to acheive incomplete recovery of eGFR
after TDF discontinuation.[18–20]Moreover, a more prolonged duration of TDF treatment
prior to discontinuation has been associated with lower chances of renal function recovery.
[18,20–22]. Of note, prolonged use of TDF at low eGFR is associatedwith higher levels of expo-
sure to tenofovir, which leads to a more rapid progression of kidney function decline.[23,24]
Early treatment switches to alternative drugs could prevent such a self-perpetratingmechanism
of injury.
A second possible explanation for our findings is that drug-related reductions of eGFR
progress more rapidly than those secondary to other common renal insults, such as hyperten-
sion or diabetes. Therefore, TDF discontinuation could be effective to prevent the damage
directly related to the drug itself only if the treatment is changed in a timely manner. Con-
versely, a less rapid or relatively stable reduction of eGFR, despite prolonged TDF exposure, is
more likely to be due to other causes and is hence less influenced by changes in the antiretrovi-
ral regimen.We cannot exclude, however, that higher rates of TDF discontinuation in patients
with higher risk of CKD and/or a steeper eGFR decline, may have diluted the effects of TDF,
thereby justifying the lack of association found between TDF use and CKD in patients exposed
to TDF for>6 months. Previous large observational studies have failed to demonstrate that
TDF exposure is an independent predictor of confirmed eGFR<60 ml/min among patients
with normal pre-TDF eGFR,mainly because proactive switches away from TDF were observed
when eGFR declined below 70 ml/min. [3] For similar reasons, no significant association
betweenTDF use and end-stage renal disease was demonstrated.[25] In our cohort, an inde-
pendent association between current eGFR and the rate of TDF discontinuation before CKD
was observed.This could have led to underestimation of the risk associated with TDF use.
In any case, observanceof mild renal impairment during treatment with TDF should
prompt an intensive and rapid work-up, and, if other amendable causes of renal damage can be
excluded, a rapid discontinuation of TDF should be effected.A timely TDF withdrawal may, in
fact, reduce the risk of progression to CKD.
Our study does have some limitations that need to be acknowledged. First, our database
lacked data on urine analysis, proteinuria, serumphosphate or other markers of tubular
Chronic Kidney Disease during Tenofovir
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damage. Hence, renal damage evaluation was based solely on eGFR,whichmay not be the best
marker of TDF-induced kidney toxicity. In addition, we were unable to adjust our analysis for co-
administration of other nephrotoxic drugs, presence of acute comorbid conditions or family his-
tory of renal diseases. These factors may have acted as unmeasured confounders. Similarly, we
could not control for genetic factors whichmay result in increased susceptibility to tenofovir-
induced renal damage.[26,27] As previously mentioned, switches from TDF did not occur at ran-
dom, but were clinician-driven; this may have led to underestimation of the risk of CKD among
patients who were kept on TDF despite mild renal impairment, as these patients could have been
perceived to be at lower risk of CKD. Finally, the majority of patients in our cohort were Cauca-
sian; hence,our findingsmay not be directly transferable to cohorts with individuals of other heri-
tage. Nonetheless, the large number of patients with previously normal eGFRwho developedmild
renal impairment under TDF is a strength of our study, as is the prolonged follow-up duration.
In conclusion, our study provides evidence that timely discontinuation of TDF (i.e., within
6 months of commencement) minimizes the risk of CKD among patients who have experi-
encedmild eGFR reduction during treatment. Given the availability of alternative treatment
options, a cautious approach in individuals with declining eGFR levels is therefore
recommended.
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